EyeGene Inc (185490) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.061x

Based on the latest financial reports, EyeGene Inc (185490) has a cash flow conversion efficiency ratio of -0.061x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.13 Billion ≈ $-2.12 Million USD) by net assets (₩50.92 Billion ≈ $34.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EyeGene Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.

EyeGene Inc - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how EyeGene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

EyeGene Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of EyeGene Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Australian Mines Ltd AU:AUZ	-0.017x
Eastern Commercial Leasing Public Company Limited BK:ECL	0.103x
BPL Limited NSE:BPL	0.003x
Energía Innovación y Desarrollo Fotovoltaico S.A. MC:EIDF	-21.569x
FingerMotion Inc NASDAQ:FNGR	-0.018x
ENERGIA IN.Y DES. EO 025 F:F63	N/A
Xali Gold Corp V:XGC	0.034x
Lotus KFM Bhd KLSE:8303	0.005x

Annual Cash Flow Conversion Efficiency for EyeGene Inc (2014–2025)

The table below shows the annual cash flow conversion efficiency of EyeGene Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see 185490 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩54.25 Billion ≈ $36.77 Million	₩-5.98 Billion ≈ $-4.05 Million	-0.110x	+54.42%
2024-12-31	₩50.32 Billion ≈ $34.10 Million	₩-12.17 Billion ≈ $-8.25 Million	-0.242x	+22.45%
2023-12-31	₩64.33 Billion ≈ $43.60 Million	₩-20.07 Billion ≈ $-13.60 Million	-0.312x	-12.09%
2022-12-31	₩66.73 Billion ≈ $45.22 Million	₩-18.57 Billion ≈ $-12.58 Million	-0.278x	+17.49%
2021-12-31	₩88.97 Billion ≈ $60.29 Million	₩-30.00 Billion ≈ $-20.33 Million	-0.337x	+55.40%
2020-12-31	₩12.90 Billion ≈ $8.74 Million	₩-9.75 Billion ≈ $-6.61 Million	-0.756x	-72.94%
2019-12-31	₩19.03 Billion ≈ $12.90 Million	₩-8.32 Billion ≈ $-5.64 Million	-0.437x	-36.42%
2018-12-31	₩23.34 Billion ≈ $15.82 Million	₩-7.48 Billion ≈ $-5.07 Million	-0.321x	-12.64%
2017-12-31	₩23.75 Billion ≈ $16.10 Million	₩-6.76 Billion ≈ $-4.58 Million	-0.285x	+23.06%
2016-12-31	₩16.19 Billion ≈ $10.97 Million	₩-5.99 Billion ≈ $-4.06 Million	-0.370x	-87.96%
2015-12-31	₩22.76 Billion ≈ $15.43 Million	₩-4.48 Billion ≈ $-3.04 Million	-0.197x	+68.29%
2014-12-31	₩3.85 Billion ≈ $2.61 Million	₩-2.39 Billion ≈ $-1.62 Million	-0.621x	--

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$29.03 Million

₩42.83 Billion KRW

Market Cap Rank

#23926 Global

#1646 in Korea

Share Price

₩1406.00

Change (1 day)

+0.07%

52-Week Range

₩1193.00 - ₩3630.00

All Time High

₩50300.00